F8 and hemophilia A: Moreover, routine prophylactic dosing with this agent eliminates the need for regular laboratory monitoring, rendering it a compelling option for prophylactic treatment in individuals with hemophilia A. Because emicizumab lacks any structural homology with FVIII, it is not anticipated to trigger the development of FVIII inhibitors and can function irrespective of the presence of FVIII inhibitors [13].